South Africa Nuclear Imaging - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The south africa nuclear imaging market size in 2026 is estimated at USD130.93 million, growing from 2025 value of USD124.63 million with 2031 projections showing USD167.79 million, growing at 5.06% CAGR over 2026-2031. This report is Segmented by Product (Equipment, Radioisotope (SPECT Radioisotopes (Technetium-99m, Thallium-201, Gallium, and More), PET Radioisotopes (Fluorine-18, Rubidium-82, Other PET Radioisotopes))), Application (Cardiology, Neurology, and More), End User (Hospitals, Diagnostic Imaging Centres, and More), and Geography. The Market Forecasts are Provided in Terms of Value (USD).

South Africa Nuclear Imaging Market Trends and Insights

Rising Oncology & CVD Incidence Driving PET/SPECT Demand

Cancer and cardiovascular disease keep imaging volumes on an upward curve as demographic aging and lifestyle transitions converge. Higher-resolution PET studies improve staging accuracy, enabling clinicians to tailor therapy plans earlier in care pathways. The 225Ac-PSMA program at Mediclinic Panorama illustrates therapeutic innovation with minimal off-target toxicity. Domestic radioisotope supply limits price volatility, keeping scan costs stable despite currency swings. Nonetheless, payer pre-authorization processes can delay access, highlighting an administrative hurdle that tempers immediate volume conversion. Governmental plans to add new scanning hubs promise scale efficiencies that may lower procedure costs over time.

Expanding Private Hospital Investments in Hybrid Imaging Suites

Life Healthcare’s multiyear, ZAR2.1 billion allocation underscores a race toward integrated PET/CT and SPECT/CT installations. Hybrid rooms compress diagnostic timelines, allowing same-day anatomical and functional studies that feed value-based care metrics. Concentration in Gauteng and Western Cape means rural patients still travel long distances, a pattern aggravated by uneven public-sector capacity. Comparative billing studies show South African private tariffs approximate those of higher-income economies despite lower national GDP per capita, suggesting premium positioning that may narrow addressable demand. Vendors now counter affordability objections with refurbished systems and usage-based payment models that shrink capital hurdles for mid-tier facilities.

High Capital & Lifecycle Costs of PET/SPECT Equipment

Purchase prices for state-of-the-art PET/CT scanners can exceed USD2 million, straining public budgets. Maintenance and calibration add recurring expenses that often outpace CPI inflation, particularly when imported parts require hard-currency outlays. Private facilities pass costs to patients, yielding tariffs comparable with OECD averages despite South Africa’s lower income baseline. Refurbished systems offer savings but raise questions about warranty coverage and detector longevity. Leasing and pay-per-scan contracts help first-time entrants, yet these models remain underused in public procurement.

Other drivers and restraints analyzed in the detailed report include:

• National Health Insurance Reimbursement Reforms
• In-Country Mo-99 Supply via Necsa SAFARI-1 Reactor
• Shortage of Nuclear Medicine Specialists & Technologists

Segment Analysis

Equipment held 54.12% South Africa nuclear imaging market share in 2025, with PET/CT upgrades accounting for the largest capital spending tranche. The South Africa nuclear imaging market size tied to equipment is projected to expand steadily as private groups refresh analog fleets and public tenders catch up to digital standards. Radioisotopes, however, post the faster 5.58% CAGR, buoyed by theranostics demand and domestic Mo-99 production security.

SPECT tracers such as Technetium-99m dominate volume, leveraging SAFARI-1’s weekly output. PET tracers led by Fluorine-18 underpin oncology and neurology protocols, while Gallium-68 enables PSMA imaging. ASP Isotopes’ enrichment of Ytterbium-176 positions the nation to support Lutetium-177 therapy production, further tilting momentum toward therapeutic isotopes. Vendors improve system uptime with AI-driven predictive maintenance, reducing unscheduled downtime that historically plagued public installations.

Complete Report Scope:

• By Product
  • Equipment
  • Radioisotope
    • SPECT Radioisotopes
      • Technetium-99m (TC-99m)
      • Thallium-201 (TI-201)
      • Gallium (Ga-67)
      • Iodine (I-123)
      • Other SPECT Radioisotopes
    • PET Radioisotopes
      • Fluorine-18 (F-18)
      • Rubidium-82 (RB-82)
      • Other PET Radioisotopes
• By Application
  • Cardiology
  • Neurology
  • Thyroid
  • Oncology
  • Other Applications
• By End User (Value)
  • Hospitals
  • Diagnostic Imaging Centres
  • Academic & Research Institutes

List of Companies Covered in this Report:

• GE HealthCare Technologies Inc.
• Siemens Healthineers
• Koninklijke Philips
• Canon
• United Imaging Healthcare Co., Ltd.
• NTP Radioisotopes SOC Ltd.
• Jubilant Radiopharma
• Novartis
• Positron Corp.
• Hermes Medical Solutions AB
• Cyclopharm Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support